

Stakeholder workshop on small particles and nanoparticles in food, 30 March – 1 April 2022



## Examples related to other considerations


Jacqueline Castenmiller, Qasim Chaudhry,  
Francesco Cubadda and Roland Franz

EFSA cross-cutting Working Group on Nanotechnologies

Trusted science for safe food



# Specific Considerations for Nanomaterial Risk Assessment





- **Agglomeration:** Due to high free energy at the surface, nanoparticles have a greater tendency of to stick together to form larger sized agglomerates. These can also de-agglomerate under certain pH/ionic conditions, or due to physical force.  
**Adequate dispersion is therefore essential.**
- **Solubility/dissolution:** Insoluble nanoparticles in a solvent form a dispersion/suspension - not a solution.  
**Stability of a dispersion is therefore essential.**
- Nanomaterials may stick to other surfaces, or sediment out of suspension.  
**Uniformity of the dose under test conditions is therefore essential.**
- **Surface characteristics:** nanoparticles may bind/adsorb other substances and act as a carrier of potentially harmful substances. They may also bind components of the test media and interfere with the assay read-out.  
**Thorough characterisation of the test material is therefore essential.**

- **Bioavailability and biokinetic behaviour** of nanomaterials can be different from conventional forms:
  - Surface chemistry/surface modifications or coatings may influence properties, behaviour, effects of a nanomaterial;  
**Consideration of surface characteristics is therefore essential.**
  - Depending on the nanomaterial, and the route of exposure, nanoparticles may cross biological membrane barriers and reach various (unintended) parts of the body.  
**Data on toxicokinetics of a nanomaterial are therefore essential.**

- **Dose metrics for toxicological testing:**
  - Mass-based dosimetry alone may not be appropriate;  
**Other metrics – such as particle number, surface area should be considered;**
  - Nanoparticles may have the potential to catalyse surface reactions;  
**Investigating surface reactivity is therefore essential.**
  - Nanoparticles may interact with biological entities close to molecular level;  
**Toxicological studies on the nanomaterial are therefore essential.**

- **Estimation of local and systemic exposure to:**
  - Nanoparticles;
  - Any released ions or other moieties.

- **Nanomaterials are not always composed of inorganic substances**
  - They can also be made from **organic, or hybrid** (inorganic/organic) substances.
  - Numerous examples of **nano-forms of organic substances** are known – including those of certain food supplements, preservatives, nutraceuticals, vitamins, antioxidants, etc.
  - Organic nanomaterials have also been used to develop **nano-scale delivery systems** for other (bio)active substances, such as biocides, pesticides, human and veterinary medicines, etc.



- In many cases, organic substances used are of natural origin, that are **claimed/assumed** by the applicants as **'safe'**.
- Like inorganic nanomaterials, **safety concerns equally apply to organic nanomaterials**, because:
  - **properties, behaviour and toxicokinetics** of both organic and inorganic substances are prone to **change at the nano-scale** – compared to conventional bulk forms.
  - nano forms of many organic substances have been reported for **much greater absorption and bioavailability** compared to the same substances in conventional bulk form. Increased uptake/bioavailability of certain substances **may cause adverse health effects**.
  - organic substances in nanoparticle form may also **cross membrane barriers** to reach those parts of the body where their conventional bulk forms would have not reached.
  - if nanoparticles of an organic substance are internalised by cells and tissues, they may act as a reservoir that continues to **release molecular/ionic forms** over long periods. This may have positive as well as negative effects in a biological system.



Therefore:

- Nano-forms of **organic or natural materials should not be automatically assumed as safe** on the basis of data corresponding to bulk forms;
- Safety assessment of nano-forms of organic/natural substances must also consider additional **small-particle related aspects**;
- A particular account should be taken of any changes in **physicochemical and biokinetic properties of the nano-form in comparison with the corresponding bulk form.**

- A specific case is that of lipophilic substances present as small particles, including nanoparticles
- If they are not marketed in lipophilic media they maintain their particulate nature when ingested
- They do not dissolve in the GI tract and thus can be generally assumed to reach the human intestine as particles
- They can follow the uptake route of lipids and partition to physiological hydrophobic environments
- Information on the physicochemical properties (e.g. solubility and  $K_{ow}$ ), toxicokinetic information and use levels

- Based on this, GI uptake may be shown to be linked to **conventional processes for the absorption of lipids and lipophilic materials** by the intestinal epithelia, such as passive transport through the cellular membranes and partitioning to physiological lipophilic environments
- **Endogenous substances** (e.g. vitamin metabolites): conventional RA may be valid and information should be compiled supporting this appraisal route
- **Exogenous components**: special care has to be exercised in order to provide a reasoned justification, in which **toxicokinetic information, uptake and distribution data are essential**

- **Nanoengineering** means an ingredient is a **novel food**
- Thus to be assessed according to 2 guidances (NF and nano); if it is a **nutrient source** according to 3 guidances (NF, NS and nano)
- For nutrient sources it is essential to show if/when the nanomaterial joins the **body pool of the nutrient** and falls under control of **homeostatic mechanisms**
- Essential to demonstrate if **particles may enter systemic circulation**, differently from dietary sources of the nutrient
- **IATAs** including **NAMs** tackling the nano-aspects are essential to provide **mechanistic knowledge** underpinning the assessment

# Why are nanomaterials used in FCMs?

## Improved Packaging with Nanomaterial Additives:

- mechanical properties (flexibility, durability, tensile strength, temperature/moisture stability, etc.)
- barrier properties against gases, water, taint, organic chemicals, u.v. light

## Active Packaging with Antimicrobial or Oxygen Scavenging Nanomaterials:

- to keep packaged food hygienic and fresh for longer

## Smart/Intelligent Packaging with Nano(bio)sensors

- to indicate quality/freshness status of packaged foodstuffs



## Nano-coatings:

- to make antimicrobial and self-cleaning food contact surfaces
- to generate a barrier layer (reduce migration/adsorption)



Concerns over consumer safety from NP exposure arise only if NP are released (migration/abrasion) from FCM into food

- Key aspect



TEM image  
LDPE-nanocomposite

In case the **solid NP** is transferred into food:  
is it sufficiently and rapidly dissolved into **ionic species (or molecules)**?

**If no** => nano-specific risk assessment

**If yes** => conventional risk assessment

## Adaptation of the solubility criterion to FCM substances

- The key consideration is that migration of nanoparticles from polymer based FCMs is generally very low (if any at all). This poses a low risk of consumer exposure to nanoparticles from the consumption of foods that was in contact with nano-composite based FCMs;
- Therefore, notwithstanding the solubility criterion provided in the Guidance, if a FCM substance has a solubility less than 33.3 g/L (i.e. not fully soluble), special considerations for small particles/nanoparticles in FCM should apply;
- However, an FCM substance may transfer from the FCM into food at a very low level that is solubilised (even though the intrinsic solubility may be <33.3 g/L);
- This discrepancy arising for the special case of FCM substances was addressed in the Guidance.

## Adaptation of the solubility criterion to FCM substances

- Under the EU Reg. 10/2011, migration limits for non-genotoxic substances are currently set at between 0.05 and 60 mg/kg (mg/L) food (food simulant).  
**=> 60 mg/kg is a generic upper migration limit for FCM substances.**
- If a FCM substance has **solubility >60 mg/L**, then its **transfer from the FCM** to food will be in **fully solubilised form** and not as particles.  
Nota bene: If migration **exceeds 60 mg/L**, then the **FCM substance will not comply with the legislative limit and will not be allowed.**
- Therefore, RA Guidance was amended to say that a conventional RA should be sufficient for a FCM substance that has **solubility >60 mg/L**, where its levels migrating into food ....  
..... can be considered to be in solubilised form on the basis of solubility/dissolution rate,  
..... or can be demonstrated to be solubilised under worse-case time-temperature food contact conditions for the packaging before ingestion of the packed food.